Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002551 · ClinicalTrials.gov registry record · Phase 3
SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,917
- Enrollment target
NCT00002551 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 1,917 participants.
The verdict
NCT00002551, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,917 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus radiation therapy in treating patients who have rectal cancer that has been surgically removed.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- RADIATION radiation therapy
- DRUG levamisole hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,917 participants |
| Start Date | 1994-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002551
The ClinicalTrials.gov registry entry for NCT00002551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,917 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00002551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002551 about?
NCT00002551 is a clinical study titled "SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for rectal cancer. PURPOSE: Randomized phase III tri...
What is the current status of trial NCT00002551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,917 participants. The study started on 1994-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00002551?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), radiation therapy (RADIATION), levamisole hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002551?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.